PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
To reduce denials and protect molecular testing revenue it is imperative for laboratories to be aware of payer policy changes. As such some payers have established their own molecular policies while other payers follow the Palmetto LCD A58710 – this LCD is quite restrictive. Humana and UHC have been identified as following the Palmetto LCD. Due to the complexity in their requirements and the limited coverage, TELCOR recommends thoroughly reading the Palmetto article for information about billing and any additional information provided within the Group the CPT falls under. These sections often contain nuances that determine whether a claim is payable.
Overall, we believe laboratories that monitor payer policy adoption, understand LCD-specific nuances, and evaluate billing strategies proactively are best positioned to handle the challenges associated with molecular testing reimbursement.
- Kwami Edwards, Chief Operations Officer, RCM
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).
The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...